Literature DB >> 26276896

Reply to "no robust evidence of lumefantrine resistance".

Mateusz M Plucinski1, Eldin Talundzic2, Lindsay Morton2, Pedro Rafael Dimbu3, Aleixo Panzo Macaia4, Filomeno Fortes3, Ira Goldman2, Naomi Lucchi2, Gail Stennies2, John R MacArthur2, Venkatachalam Udhayakumar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26276896      PMCID： PMC4538470          DOI： 10.1128/AAC.01355-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.

Authors:  Mateusz M Plucinski; Eldin Talundzic; Lindsay Morton; Pedro Rafael Dimbu; Aleixo Panzo Macaia; Filomeno Fortes; Ira Goldman; Naomi Lucchi; Gail Stennies; John R MacArthur; Venkatachalam Udhayakumar
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  No robust evidence of lumefantrine resistance.

Authors:  Kamal Hamed; Kelli Kuhen
Journal:  Antimicrob Agents Chemother       Date:  2015-09       Impact factor: 5.191

3.  Coartem (artemether-lumefantrine) in Africa: the beginning of the end?

Authors:  Ian M Hastings; Stephen A Ward
Journal:  J Infect Dis       Date:  2005-10-01       Impact factor: 5.226

4.  Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy.

Authors:  Madeline Slater; Moses Kiggundu; Chris Dokomajilar; Moses R Kamya; Nathan Bakyaita; Ambrose Talisuna; Philip J Rosenthal; Grant Dorsey
Journal:  Am J Trop Med Hyg       Date:  2005-08       Impact factor: 2.345

5.  The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.

Authors:  Steffen Borrmann; William M Sallas; Sonia Machevo; Raquel González; Anders Björkman; Andreas Mårtensson; Mary Hamel; Elizabeth Juma; Judy Peshu; Bernhards Ogutu; Abdoulaye Djimdé; Umberto D'Alessandro; Anne-Claire Marrast; Gilbert Lefèvre; Steven E Kern
Journal:  Trop Med Int Health       Date:  2010-02-17       Impact factor: 2.622

6.  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

Authors:  Patrice Piola; Carole Fogg; Francis Bajunirwe; Samuel Biraro; Francesco Grandesso; Eugene Ruzagira; Joseph Babigumira; Isaac Kigozi; James Kiguli; Juliet Kyomuhendo; Laurent Ferradini; Walter Taylor; Francesco Checchi; Jean-Paul Guthmann
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

Review 7.  Epidemiology of drug-resistant malaria.

Authors:  Chansuda Wongsrichanalai; Amy L Pickard; Walther H Wernsdorfer; Steven R Meshnick
Journal:  Lancet Infect Dis       Date:  2002-04       Impact factor: 25.071

8.  The perils of PCR: can we accurately 'correct' antimalarial trials?

Authors:  Jonathan J Juliano; Nahla Gadalla; Colin J Sutherland; Steven R Meshnick
Journal:  Trends Parasitol       Date:  2010-01-18

Review 9.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.

Authors:  Kasia Stepniewska; Nicholas J White
Journal:  Malar J       Date:  2006-12-22       Impact factor: 2.979

10.  Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms.

Authors:  Maja Malmberg; Pedro E Ferreira; Joel Tarning; Johan Ursing; Billy Ngasala; Anders Björkman; Andreas Mårtensson; José P Gil
Journal:  J Infect Dis       Date:  2012-12-05       Impact factor: 5.226
  10 in total
  1 in total

Review 1.  Plasmodium falciparum drug resistance in Angola.

Authors:  Cláudia Fançony; Miguel Brito; Jose Pedro Gil
Journal:  Malar J       Date:  2016-02-09       Impact factor: 2.979
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.